Uterine Fibroids · 11 min read · 2026-05-16
VEGFR2 Inhibition, mTOR/Wnt Pathway Dysregulation, and VDR Anti-Proliferative Signaling in Uterine Fibroids: Mechanistic Evidence for Nutritional Intervention
Uterine leiomyomas (fibroids) affect 70–80% of women by age 50, with symptomatic prevalence — heavy menstrual bleeding, pelvic pressure, and pregnancy complications — estimated at 25–50% of reproductive-age women. The racial disparity is substantial and epidemiologically well-established: Black women experience 2–3× higher incidence, earlier onset (average 6–9 years earlier), greater lesion burden (larger, more numerous fibroids), and higher rates of surgical intervention compared to white women. Critically, Black women also demonstrate higher rates of vitamin D deficiency — a finding that converges with fibroid biology given the anti-proliferative role of VDR signaling in leiomyoma smooth muscle cells.
At the molecular level, fibroids are characterized by somatic mutations in MED12 (found in approximately 70% of cases), EIF4A1, HMGA2, or FH genes — initiating events that dysregulate growth factor signaling, extracellular matrix remodeling, and steroid hormone responsiveness. The downstream pathology involves constitutive activation of Wnt/β-catenin and mTOR pathways driving smooth muscle cell (SMC) proliferation, VEGF-mediated neoangiogenesis supporting lesion growth, and local estrogen/progesterone hypersensitivity. Each of these axes presents a tractable target for nutritional modulation, with the strongest clinical evidence accumulated for EGCG (VEGFR2 inhibition) and vitamin D (VDR-mediated anti-proliferation).
EGCG VEGFR2 Inhibition: Mechanism and Clinical Evidence
[Image: VEGF/VEGFR2 signaling cascade in fibroid vasculature: VEGF-A → VEGFR2 kinase domain → PI3K/Akt + PLCγ/ERK + FAK/Src branches, with EGCG gallate moiety binding at ATP pocket labeled as inhibition point]
Epigallocatechin-3-gallate (EGCG), the predominant catechin in green tea extract, functions as a competitive inhibitor of VEGFR2 (KDR/Flk-1) tyrosine kinase — the primary signal transducer for VEGF-A in fibroid-associated vasculature. VEGF-A binding to VEGFR2 activates three downstream cascades relevant to fibroid growth: PLCγ-PKC-ERK (endothelial proliferation), PI3K-Akt (endothelial survival and SMC growth factor secretion), and FAK-Src (endothelial migration and tube formation). EGCG's gallate moiety directly occupies the ATP-binding pocket of VEGFR2's kinase domain, reducing autophosphorylation at Tyr1175 and Tyr1214 — the residues required for PLCγ and PI3K coupling respectively.
The clinical evidence from the Wahab et al. double-blind RCT is the most directly applicable dataset: 800mg/day EGCG (two 400mg doses) over 4 months in premenopausal women with symptomatic fibroids produced a 32.6% mean reduction in total fibroid volume by ultrasound measurement, compared to a 24.3% volume increase in the placebo arm — a net differential of approximately 57%. Hemoglobin increased by 10.3% in the EGCG group (reflecting reduced menorrhagia), and self-reported symptom scores improved significantly on the UFS-QOL scale. This RCT used standardized EGCG extract with ≥45% EGCG content — a formulation specification critical for replicating outcomes, as tea-extracted catechin products show wide variability in actual EGCG concentration.
Wnt/β-Catenin and mTOR Pathway Dysregulation in Fibroid SMC Proliferation
[Image: Wnt/β-catenin pathway in fibroid SMCs: MED12 mutation → destruction complex failure → β-catenin nuclear translocation → cyclin D1/MYC transcription, with quercetin CK1α activation and β-catenin degradation site labeled]
The canonical Wnt/β-catenin pathway is constitutively activated in MED12-mutant fibroids via multiple mechanisms: reduced expression of destruction complex components (APC, Axin1), increased β-catenin nuclear translocation, and TCF/LEF transcription factor-driven expression of cyclin D1, MYC, and survivin — core cell cycle entry and apoptosis resistance genes. MED12 mutations specifically affect a region of Mediator complex subunit 12 that normally suppresses β-catenin transcriptional activity; mutant MED12 loses this suppressive function, releasing constitutive Wnt target gene expression.
Quercetin dihydrate (500–1,000mg/day) functions as a dual Wnt/mTOR inhibitor in fibroid SMCs. Its Wnt inhibition occurs via CK1α activation — enhancing β-catenin phosphorylation and proteasomal degradation — and through direct β-catenin/TCF interaction disruption at the nuclear level. The mTOR pathway in fibroids is hyperactivated downstream of PI3K/Akt (driven by IGF-1/insulin receptor signaling in estrogen-primed SMCs), driving protein synthesis, cell size increase, and autophagy suppression. Quercetin inhibits mTORC1 via Akt Ser473 dephosphorylation and direct FKBP12-rapamycin binding domain interactions. In leiomyoma cell lines, quercetin at 50μM reduces SMC viability by approximately 45% and reduces fibronectin and collagen type I secretion — addressing both the proliferative and fibrotic components of lesion architecture.
VDR Signaling in Fibroid Tissue: Anti-Proliferative Mechanisms and Racial Disparity
[Image: VDR signaling in fibroid smooth muscle cell: calcitriol → VDR/RXR → VDRE binding → TGF-β3 suppression + PTEN upregulation + COMT reduction, with racial disparity in 25(OH)D levels and fibroid incidence correlation graph]
Vitamin D receptor (VDR) is expressed in uterine leiomyoma tissue, where its activation by 1,25-dihydroxyvitamin D3 (calcitriol) produces anti-proliferative and pro-apoptotic effects through multiple gene regulatory programs. VDR/RXR heterodimer binding to vitamin D response elements (VDREs) in fibroid SMC nuclei suppresses TGF-β3 expression — a key driver of fibroid extracellular matrix overproduction (type I collagen, fibronectin) — and upregulates PTEN, reducing PI3K/Akt pathway activity. VDR activation also suppresses catechol-O-methyltransferase (COMT) expression in fibroids, impairing local estrogen inactivation and potentially blunting estrogen-driven growth signals through a distinct mechanism.
The epidemiological intersection of fibroid burden and vitamin D deficiency is compelling: Black women in the United States have a 25-hydroxyvitamin D [25(OH)D] prevalence of deficiency (<20 ng/mL) of approximately 76% compared to 31% in white women, driven by melanin's photoprotective reduction of cutaneous vitamin D synthesis. This racial differential in vitamin D status maps precisely onto the demographic disparity in fibroid incidence, earlier onset, and lesion severity — an association that has reached statistical significance across multiple large cohort studies (ORs of 0.5–0.7 for fibroid risk per 10 ng/mL increase in 25(OH)D). Optimal supplementation targets ≥40 ng/mL 25(OH)D, typically requiring 2,000–4,000 IU/day in women with baseline deficiency.
Clinical Protocol Integration and Monitoring Parameters
[Image: Fibroid supplement mechanism integration diagram: EGCG (VEGFR2 → angiogenesis) + Vitamin D (VDR → TGF-β3/PTEN) + Quercetin (Wnt/β-catenin + mTOR) with non-overlapping pathway arrows and monitoring parameter timeline]
The mechanistically rational supplement protocol for uterine fibroids combines EGCG (400–800mg/day from ≥45% standardized extract), vitamin D3 targeting 40–60 ng/mL serum 25(OH)D, and quercetin (500–1,000mg/day) — addressing VEGFR2-mediated angiogenesis, VDR anti-proliferative signaling, and Wnt/β-catenin/mTOR SMC proliferation respectively. These mechanisms are non-overlapping and potentially synergistic at the lesion level: angiogenesis inhibition (EGCG) reduces lesion perfusion while VDR and quercetin reduce SMC proliferation.
Clinical monitoring in the context of this protocol requires baseline and 4–6 month ultrasound assessment (fibroid volume measurement by 3D volumetry provides the most sensitive change detection), serum 25(OH)D measurement every 3 months during repletion, and hemoglobin/ferritin given menorrhagia burden. The Wahab et al. EGCG RCT used ultrasound at 0 and 4 months as the primary outcome measure, establishing a monitoring cadence precedent. For EGCG specifically, liver function monitoring (ALT, AST) at baseline and 3 months is appropriate at doses ≥800mg/day, as isolated hepatotoxicity cases have been reported with high-dose green tea extract — though at lower rates than with green tea extract containing epigallocatechin (EGC) rather than purified EGCG. Dose reduction to 400mg/day is appropriate if ALT exceeds 2× upper limit of normal.
The bottom line
Uterine fibroids represent a convergence of angiogenic, proliferative, and extracellular matrix dysregulation — each axis accessible to mechanism-matched nutritional intervention. EGCG's VEGFR2 inhibition produced a −32.6% fibroid volume reduction in RCT conditions. Vitamin D VDR signaling addresses both the anti-proliferative TGF-β3/PTEN axis and the racially patterned deficiency that correlates with excess disease burden. Quercetin disrupts the Wnt/β-catenin and mTOR proliferation cascade driving SMC hyperplasia. Selene's personalization engine incorporates fibroid history, menorrhagia severity, and baseline vitamin D status to calibrate this protocol, with monitoring guidance integrated into the platform's tracking layer.
Questions
What EGCG dose and formulation specification replicates the Wahab et al. −32.6% volume reduction finding?
The Wahab et al. RCT used 800mg/day total EGCG (400mg × 2) from a standardized green tea extract with ≥45% EGCG by weight. Product EGCG content is highly variable — many commercial green tea extracts deliver only 10–25% EGCG. The 400mg/dose frequency ensures sustained VEGFR2 inhibition across the day given EGCG's plasma half-life of approximately 3.4 hours. Lower doses or non-standardized extracts should not be assumed to produce equivalent volumetric outcomes.
Is the VDR-fibroid evidence strong enough to justify 25(OH)D target of 40–60 ng/mL specifically for fibroids?
Cohort data shows ORs of 0.5–0.7 for fibroid risk per 10 ng/mL increase in 25(OH)D across multiple studies, with the protective association appearing above 40 ng/mL. Mechanistic data confirms VDR expression in fibroid tissue with demonstrable TGF-β3 and PTEN regulation. The 40–60 ng/mL target is consistent with functional VDR saturation. RCT-level evidence specifically on vitamin D supplementation for fibroid regression is limited — but the safety profile of repleting to this range is favorable, particularly in deficient Black women.
Does quercetin have sufficient bioavailability to achieve Wnt/β-catenin inhibition at 500mg oral dosing?
Standard quercetin aglycone has oral bioavailability of 0.3–3%. Quercetin dihydrate and quercetin phytosome formulations achieve higher plasma concentrations. At 500–1,000mg/day oral dosing with food (fat improves absorption), plasma quercetin typically reaches 0.2–1.5μM. In vitro Wnt/β-catenin inhibition studies used 10–50μM — a gap that raises questions about whether plasma concentrations are sufficient for direct SMC β-catenin degradation. Tissue accumulation in uterine tissue may be higher than plasma levels suggest, and quercetin metabolites (isorhamnetin, tamarixetin) retain partial biological activity.
What is the risk profile for EGCG hepatotoxicity at fibroid-relevant doses, and how should it be monitored?
EGCG hepatotoxicity has been documented primarily with high-dose green tea extracts in fasted states at ≥800mg EGCG/day. The proposed mechanism is mitochondrial uncoupling at hepatocyte level at high intracellular EGCG concentrations, potentiated by fasting-state hepatic uptake. The Wahab et al. trial at 800mg/day in fed state showed no hepatic safety signals. Monitoring ALT/AST at baseline and 3 months is prudent at this dose. Taking EGCG with food substantially reduces peak hepatic concentrations and is the standard clinical recommendation.
Build an evidence-based Uterine Fibroids protocol.
Selene's personalization engine maps your hormonal profile to peer-reviewed ingredient stacks, adjusted for your cycle phase and symptom cluster.
View the Uterine Fibroids clinical profile →